FDA asks Lilly for liver data
The U.S. FDA has asked Eli Lilly to collect additional post‑marketing safety data on liver injury after the agency recently approved Lilly’s new weight‑loss pill (reuters.com). The request is focused specifically on monitoring liver outcomes as part of required post‑approval studies (reuters.com).
The Food and Drug Administration approved Eli Lilly’s new obesity pill on April 1, then told the company to keep tracking possible drug-related liver injury after launch. (accessdata.fda.gov) The pill is Foundayo, the brand name for orforglipron, a once-daily glucagon-like peptide-1 drug taken by mouth. The approval letter says Lilly must finish an ongoing trial called ACHIEVE-4 and provide added safety data on major heart events and the “potential for drug-induced liver injury.” (accessdata.fda.gov) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel fuller and eat less. Foundayo is approved for adults with obesity, or adults with overweight plus at least one weight-related medical condition, alongside diet and exercise. (fda.gov) (accessdata.fda.gov) The approval moved unusually fast. The Food and Drug Administration said it cleared Foundayo 50 days after filing and 294 days before the original Prescription Drug User Fee Act target date of January 20, 2027, under the Commissioner’s National Priority Voucher pilot program. (fda.gov) That speed put a post-marketing study in the spotlight. A post-marketing requirement means the drug can be sold, but the company still has to collect more data in the real world or in ongoing trials after approval. (fda.gov) (accessdata.fda.gov) Lilly pitched Foundayo as the first weight-loss glucagon-like peptide-1 pill that can be taken without food or water restrictions. The company said prescriptions were accepted immediately after approval, with shipping through LillyDirect beginning April 6 and wider retail pharmacy availability following. (investor.lilly.com) (medical.lilly.com) In Lilly’s Phase 3 ATTAIN-1 obesity trial, participants on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4% of body weight, at 72 weeks. Lilly also said the study showed improvements in waist size, triglycerides, non-high-density lipoprotein cholesterol and systolic blood pressure. (investor.lilly.com 1) (investor.lilly.com 2) The label carries a boxed warning about thyroid C-cell tumors based on findings seen with this drug class in rodents, and it says Foundayo is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The prescribing information also warns about pancreatitis and severe gastrointestinal reactions. (accessdata.fda.gov) The next test is no longer whether Foundayo can reach pharmacy shelves. It is whether Lilly’s required follow-up data can show the pill’s convenience and weight-loss results hold up alongside a clearer picture of liver safety. (accessdata.fda.gov)
